A randomized, double-blind, split-face study of topical silymarin versus 2% hydroquinone cream in melasma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210729003

Enrollment

Registered

2021-07-29

Start date

2017-05-22

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma Melasma, Silymarin, Hydroquinone, Silibinin

Interventions

apply twice daily on one side of the face,apply twice daily on the other side of the face

Active Comparator Drug,Active Comparator Drug

Silymarin cream,2% hydroquinone cream

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 25 female patients with epidermal or mixed-type melasma on both cheeks

Exclusion criteria

Exclusion criteria: 1.Patients with pregnancy and lactation 2. Received hormonal therapy or contraceptive pills within 1 year 3. Received any topical treatment within 1 month 4. Received laser treatment within 3 months 5. Having other facial dermatologic conditions or present of any life-threatening underlying diseases

Design outcomes

Primary

Measure	Time frame
The severity of melasma 12 weeks modified MASI score, relative lightness index,Patient-self assessment 12 weeks VAS	—

Secondary

Measure	Time frame
Adverse effects 12 weeks All occurring adverse effects of silymarin and hydroquinone were recorded at each visit	—

Countries

Thailand

Contacts

Public ContactPenpun Wattanakrainitya

Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University

maypenpun@gmail.com6622011141

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026